Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

被引:91
作者
Garraud, O. [1 ,2 ]
Heshmati, F. [3 ]
Pozzetto, B. [1 ,4 ]
Lefrere, F. [5 ]
Girot, R. [6 ,7 ]
Saillol, A. [8 ]
Laperche, S. [2 ]
机构
[1] Univ Lyon, Fac Med St Etienne, F-42023 St Etienne, France
[2] Inst Natl Transfus Sanguine, F-75015 Paris, France
[3] Hop Cochin, AP HP, F-75005 Paris, France
[4] CHU St Etienne, Lab Agents Infect & Hyg, F-42055 St Etienne, France
[5] Grp Necker Enfants Malad, AP HP, F-75015 Paris, France
[6] Hop Tenon, AP HP, F-75020 Paris, France
[7] Univ Paris 06, F-75005 Paris, France
[8] Ctr Transfus Sanguine Armees, F-92140 Clamart, France
关键词
Plasma therapy; Convalescent plasma; Neutralizing antibodies; Therapeutic plasma; Infectious disease; Transfusion; Ebolavirus infection; ACUTE RESPIRATORY SYNDROME; CONVALESCENT BLOOD-PRODUCTS; EBOLA-VIRUS DISEASE; LASSA FEVER; PASSIVE IMMUNOTHERAPY; HONG-KONG; INTRAVENOUS IMMUNOGLOBULIN; HISTORICAL-PERSPECTIVE; HYPERIMMUNE GLOBULINS; TRANSFUSION THERAPY;
D O I
10.1016/j.tracli.2015.12.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Plasma therapy consists in bringing to a patient in need - in general suffering a severe, resistant to current therapy, and even lethal infection - plasma or specific, fractioned, antibodies, along with other immunoglobulins and possibly healing factors that can be obtained from immunized blood donors; donors (voluntary and benevolent) can be either actively immunized individuals or convalescent persons. Plasma therapy has been used since the Spanish flu in 1917-1918, and regularly then when viral epidemics threatened vulnerable populations, the last reported occurrence being the 2013-2015 Ebola virus outbreak in West Africa. The precise action mechanism of plasma therapy is not fully delineated as it may function beyond purified, neutralizing antibodies. (C) 2015 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:39 / 44
页数:6
相关论文
共 66 条
[1]  
Abela IA, 2010, CURR PHARM DESIGN, V16, P3754, DOI 10.2174/138161210794079245
[2]  
AVENARD G, 1979, NOUV PRESSE MED, V8, P673
[3]   A study in scarlet-convalescent plasma for severe influenza [J].
Beigel, John H. ;
Luke, Thomas C. .
CRITICAL CARE MEDICINE, 2012, 40 (03) :1027-1028
[4]   Who should donate blood? Policy decisions on donor deferral criteria should protect recipients and be fair to donors [J].
Brailsford, S. R. ;
Kelly, D. ;
Kohli, H. ;
Slowther, A. ;
Watkins, N. A. .
TRANSFUSION MEDICINE, 2015, 25 (04) :234-238
[5]   Ebola virus convalescent blood products: Where we are now and where we may need to go [J].
Burnouf, Thierry ;
Seghatchian, Jerard .
TRANSFUSION AND APHERESIS SCIENCE, 2014, 51 (02) :120-125
[6]   Ebola: a call for blood transfusion strategy in sub-Saharan Africa [J].
Burnouf, Thierry ;
Emmanuel, Jean ;
Mbanya, Dora ;
El-Ekiaby, Magdy ;
Murphy, William ;
Field, Stephen ;
Allain, Jean-Pierre .
LANCET, 2014, 384 (9951) :1347-1348
[7]   Use of convalescent plasma therapy in SARS patients in Hong Kong [J].
Cheng, Y ;
Wong, R ;
Soo, YOY ;
Wong, WS ;
Lee, CK ;
Ng, MHL ;
Chan, P ;
Wong, KC ;
Leung, CB ;
Cheng, G .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2005, 24 (01) :44-46
[8]   Large-scale Convalescent Blood and Plasma Transfusion Therapy for Ebola Virus Disease [J].
Colebunders, Robert L. ;
Cannon, Robert O. .
JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (08) :1208-1210
[9]   Prophylaxis and Therapy for Chikungunya Virus Infection [J].
Couderc, Therese ;
Khandoudi, Nassirah ;
Grandadam, Marc ;
Visse, Catherine ;
Gangneux, Nicolas ;
Bagot, Sebastien ;
Prost, Jean-Francois ;
Lecuit, Marc .
JOURNAL OF INFECTIOUS DISEASES, 2009, 200 (04) :516-523
[10]  
Delamou A, 2015, CLIN INFECT DIS